首页 | 期刊导航 | 学习空间 | 退出

期刊文章列表

  • Jian Gao1,Zhigui Wu1,Mingxia Zhao1,2,Rui Zhang3,Manru Li1,Dongdong Sun4,Haibo Cheng4,Xianjia Qi5,Yuxian Shen2,Qiang Xu1,6,Hongqi Chen7,Dijun Chen1,Yang Sun1,6(State Key Laboratory of Pharmaceutical Biotechnology,Chemistry and Biomedicine Innovation Center(Chem BIC),School of Life Sciences,Nanjing University;Biopharmaceutical Research Institute,School of Basic Medical Sciences,Anhui Medical University;Department of Colorectal Surgery,Cancer Hospital of China Medical University,Liaoning Cancer Hospital & Institute;The First Clinical College of Nanjing University of Chinese Medicine;Shanghai Xu Ran Biotechnology Co.,Ltd.;Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy,Xuzhou Medical University;Department of General Surgery,Shanghai Jiao Tong University Affiliated Sixth People's Hospital).Allosteric inhibition reveals SHP2-mediated tumor immunosuppression in colon cancer by single-cell transcriptomics[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Yuanyuan Wang1,2,Bin Wei1,3,Danping Wang1,2,Jingjing Wu3,Jianhua Gao4,Haiqing Zhong4,Yang Sun4,Qiang Xu4,Wen Liu4,Yanhong Gu1,2,Wenjie Guo4(Department of Oncology,the First Affiliated Hospital of Nanjing Medical University;Cancer Rehabilitation Center,Jiangsu Province Hospital;Department of Oncology,the Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University;State Key Laboratory of Pharmaceutical Biotechnology,School of Life Sciences,Nanjing University).DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS-STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Long Chen1,Jing Zhang2,Xinjing Wang3,4,Yu Li1,Lu Zhou5,Xiongxiong Lu3,4,Guoqiang Dong1,Chunquan Sheng1(School of Pharmacy,Second Military Medical University;Department of Pathology,Changzheng Hospital,Second Military Medical University;Department of General Surgery,Pancreatic Disease Center,Ruijin Hospital,Shanghai Jiao Tong University;Research Institute of Pancreatic Diseases,Shanghai Jiao Tong University School of Medicine;Department of Medicinal Chemistry,School of Pharmacy,Fudan University).Discovery of novel KRAS-PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Hongyu Sun1,2,Siyu He2,3,Li Wu2,Zeying Cao2,3,Xian Sun2,3,4,Mingwei Xu5,Shan Lu2,6,Mingdi Xu7,Baoming Ning7,Huimin Sun8,7,Tiqiao Xiao5,Peter York2,Xu Xu1,Xianzhen Yin2,4,Jiwen Zhang1,2,8(School of Chemical and Environmental Engineering,Shanghai Institute of Technology;Center for Drug Delivery System,Shanghai Institute of Materia Medica,Chinese Academy of Sciences;University of Chinese Academy of Sciences;Center for MOST and Image Fusion Analysis,Shanghai Institute of Materia Medica,Chinese Academy of Sciences;Shanghai Synchrotron Radiation Facility/Zhangjiang Lab,Shanghai Advanced Research Institute,Chinese Academy of Sciences;School of Materials Science and Engineering,Center for Supramolecular Chemistry and Catalysis,Department of Chemistry,Shanghai University;National Institutes for Food and Drug Control;NMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients,National Institutes for Food and Drug Control).Bridging the structure gap between pellets in artificial dissolution media and in gastro-intestinal tract in rats[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Tuo Shao1,2,Zhen Chen1,Jian Rong1,Vasily Belov1,3,Jiahui Chen1,Andre Jeyarajan2,Xiaoyun Deng1,Hualong Fu1,Qingzhen Yu1,Steve H.Rwema2,Wenyu Lin2,Mikhail Papisov1,3,Lee Josephson1,Raymond T.Chung2,Steven H.Liang1(Division of Nuclear Medicine and Molecular Imaging,Department of Radiology,Massachusetts General Hospital and Harvard Medical School;Liver Center and Gastrointestinal Division,Department of Medicine,Massachusetts General Hospital,Harvard Medical School;Shriners Hospitals for Children-Boston Boston).[18F]MAGL-4-11 positron emission tomography molecular imaging of monoacylglycerol lipase changes in preclinical liver fibrosis models[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Yingtong Cui1,2,Ying Huang1,2,Xuejuan Zhang1,2,Xiangyun Lu3,Jun Xue4,Guanlin Wang2,Ping Hu1,Xiao Yue2,Ziyu Zhao2,5,Xin Pan2,Chuanbin Wu1,2(School of Pharmaceutical Science,Jinan University;School of Pharmaceutical Sciences,Sun Yat-sen University;Micromeritics Instrument (Shanghai) Ltd.;MEGGLE Group Shanghai Representative Office;Department of Pharmacology,Zhongshan School of Medicine,Sun Yat-sen University).A real-time and modular approach for quick detection and mechanism exploration of DPIs with different carrier particle sizes[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Zhangxu He1,Haomiao Jiao1,Qi An1,Xin Zhang1,Dan Zengyangzong1,Jiale Xu1,Hongmin Liu1,Liying Ma1,2,Wen Zhao1(State Key Laboratory of Esophageal Cancer Prevention and Treatment,Key Laboratory of Advanced Pharmaceutical Technology,Ministry of Education of China,School of Pharmaceutical Sciences,Zhengzhou University;China Meheco Topfond Pharmaceutical Co).Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Qi Hu1,2,Lanlan Jia1,2,Xiaolin Zhang1,2,Aihong Zhu1,2,Sicen Wang1,2,Xiaoyu Xie1,2(School of Pharmacy,Health Science Center,Xi'an Jiaotong University;Shaanxi Engineering Research Center of Cardiovascular Drugs Screening & Analysis).Accurate construction of cell membrane biomimetic graphene nanodecoys via purposeful surface engineering to improve screening efficiency of active components of traditional Chinese medicine[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Shuangquan Gou1,2,3,Nanxi Chen2,Xiaoai Wu4,Menghang Zu2,3,Shixiong Yi2,Binwu Ying5,Fangyin Dai2,Bowen Ke1,Bo Xiao2,3(Laboratory of Anesthesiology & Critical Care Medicine,Department of Anesthesiology,West China Hospital,Sichuan University;State Key Laboratory of Silkworm Genome Biology,College of Sericulture,Textile and Biomass Sciences,Southwest University;Chongqing Key Laboratory of Soft-Matter Material Chemistry and Function Manufacturing,School of Materials and Energy,Southwest University;Department of Nuclear Medicine,West China Hospital,Sichuan University;Department of Laboratory Medicine,West China Hospital,Sichuan University).Multi-responsive nanotheranostics with enhanced tumor penetration and oxygen self-producing capacities for multimodal synergistic cancer therapy[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Junxia Wang,Minghua Chen,Mengyan Wang,Wenxia Zhao,Conghui Zhang,Xiujun Liu,Meilian Cai,Yuhan Qiu,Tianshu Zhang,Huimin Zhou,Wuli Zhao,Shuyi Si,Rongguang Shao(Key Laboratory of Antibiotic Bioengineering,Ministry of Health,Laboratory of Oncology,Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences and Peking Union Medical College).The novel ER stress inducer Sec C triggers apoptosis by sulfating ER cysteine residues and degrading YAP via ER stress in pancreatic cancer cells[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Heng Li1,2,Yao Zhang3,Moting Liu1,2,Chen Fan1,Chunlan Feng1,Qiukai Lu1,2,Caigui Xiang1,2,Huimin Lu1,2,Xiaoqian Yang1,Bing Wu1,2,Duowu Zou3,Wei Tang1,2(Laboratory of Anti-inflammation and Immunopharmacology,Shanghai Institute of Materia Medica,Chinese Academy of Sciences;School of Pharmacy,University of Chinese Academy of Sciences;Department of Gastroenterology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine).Targeting PDE4 as a promising therapeutic strategy in chronic ulcerative colitis through modulating mucosal homeostasis[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Rong Guo,Miao Deng,Xuan He,Mengmeng Li,Jiaxin Li,Penghui He,Houqin Liu,Man Li,Zhirong Zhang,Qin He(Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province,Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology,West China School of Pharmacy,Sichuan University).Fucoidan-functionalized activated platelet-hitchhiking micelles simultaneously track tumor cells and remodel the immunosuppressive microenvironment for efficient metastatic cancer treatment[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Cong Liu1,Anzhi Hu1,Huijuan Chen1,Jing Liang2,Mancang Gu1,Yang Xiong1,Chao-Feng Mu1,3(School of Pharmaceutical Sciences,Zhejiang Chinese Medical University;Center for Synthetic Biochemistry,Shenzhen Institute of Synthetic Biology,Shenzhen Institutes of Advanced Technology,Chinese Academy of Sciences;Engineering Research Center of Clinical Functional Materials and Diagnosis & Treatment Devices of Zhejiang Province,Wenzhou Institute of Biomaterials and Engineering).The osteogenic niche-targeted arsenic nanoparticles prevent colonization of disseminated breast tumor cells in the bone[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Lei Fang1,2,Zitong Zhao2,Jue Wang2,Ping Xiao2,Xiangshi Sun2,Yaping Ding1,Pengcheng Zhang2,3,Dangge Wang2,4,3,Yaping Li2,4,3(Collage of Sciences,Shanghai University;State Key Laboratory of Drug Research & Center of Pharmaceutics,Shanghai Institute of Materia Medica,Chinese Academy of Sciences;Yantai Key Laboratory of Nanomedicine & Advanced Preparations,Yantai Institute of Materia Medica;School of Pharmacy,Yantai University).Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Liang Chen1,Jie Zhang1,Zhun Lin1,Ziyan Zhang1,Miao Mao1,Jiacheng Wu1,Qian Li2,3,Yuanqing Zhang1,Chunhai Fan2,3(School of Pharmaceutical Sciences,Sun Yat-sen University;School of Chemistry and Chemical Engineering,Frontiers Science Center for Transformative Molecules and National Center for Translational Medicine,Shanghai Jiao Tong University;Institute of Molecular Medicine,Shanghai Key Laboratory for Nucleic Acids Chemistry and Nanomedicine,Renji Hospital,School of Medicine,Shanghai Jiao Tong University).Pharmaceutical applications of framework nucleic acids[J].Acta Pharmaceutica Sinica B,2022,第1期
  • Benyu Nan1,2,Zirui Zhao3,Kanglun Jiang1,Xi Gu4,Huawei Li5,6,7,8,Xinsheng Huang1(Department of Otorhinolaryngology-Head and Neck Surgery,Zhongshan Hospital,Fudan University;Department of Otorhinolaryngology-Head and Neck Surgery,Wenzhou Medical University,Affiliated Hospital 2;Department of Otolaryngology,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine;Department of Otolaryngology,the First Affiliated Hospital of Fujian Medical University;ENT Institute and Department of Otorhinolaryngology,Eye & ENT Hospital,State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science,Fudan University;Institutes of Biomedical Sciences,Fudan University;NHC Key Laboratory of Hearing Medicine (Fudan University);The Institutes of Brain Science and the Collaborative Innovation Center for Brain Science,Fudan University).Astaxanthine attenuates cisplatin ototoxicity in vitro and protects against cisplatin-induced hearing loss in vivo[J].Acta Pharmaceutica Sinica B,2022,第1期
首页 上一页 10 11 12 尾页 共有12页,转到 页

帮助 | 繁體中文 | 关于发现 | 联系我们

超星发现系统 Copyright©·powered by 超星

客服电话:4008236966